| Literature DB >> 11378956 |
Abstract
Antibody-based therapeutics are currently being tested in an increasingly diverse range of therapeutic modalities. Many different engineered formats for the antibody molecule and multiple methods for raising and tailoring binding specificities are currently available. Comparison of the relative function and efficacy of these molecules and the many competing methods for their production is crucial for making an informed selection of a new therapeutic entity. In addition, these choices may be influenced by the attached intellectual property burden.Mesh:
Substances:
Year: 2001 PMID: 11378956
Source DB: PubMed Journal: Curr Opin Drug Discov Devel ISSN: 1367-6733